Department of Medical Imaging and Interventional Radiology, Cancer Center and State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China.
Cancer Biol Ther. 2012 Aug;13(10):840-7. doi: 10.4161/cbt.20834. Epub 2012 Aug 1.
Primary brain tumors have always been associated with high morbidity and mortality. Glioma is the most common type of malignant brain tumors,with a high probability of recurrence after surgical excision and with poor prognosis.The purpose of this study was to compare the therapeutic efficacy of computed tomography (CT)-guided interstitial (125)I seed implantation with traditional radiochemotherapy for treatment of recurrent gliomas.
The response rate at 1, 3, 6 and 12 months after (125)I seed implantation was 68.6, 74.3, 77.1 and 62.8% respectively, which was significantly higher than the group treated with the conventional chemoradiation protocol (p < 0.05). Patients exposed to (125)I seed implantation had a median survival of 29.0 months, whereas the median survival of those treated with traditional radiochemotherapy was 19.0 months. The difference observed between the two groups was significant. There were no severe complications or mortality associated with either treatment, except for one case of intracerebral hemorrhage around the tumor area in the (125)I seed implants group.
From November 2002 to May 2010, 73 consecutive patients with recurrent gliomas were treated with CT-guided (125)I seed implantation (35 cases) or traditional radiochemotherapy (38 cases). Patients were followed up after treatment and the therapeutic effect was evaluated by comparing the response and survival rates of the two groups. In particular, patients treated with (125)I seed implantation were monitored for adverse side effects.
CT-guided (125)I seed implantation is safe and well-tolerated and more importantly, shows superior efficacy compared with conventional radiochemotherapy. This suggests that CT-guided (125)I seed implantation could be an alternative approach for recurrent gliomas.
原发性脑肿瘤一直与高发病率和死亡率相关。神经胶质瘤是最常见的恶性脑肿瘤，手术切除后复发概率高，预后差。本研究旨在比较 CT 引导下间质（125）I 种子植入与传统放化疗治疗复发性神经胶质瘤的疗效。
（125）I 种子植入后 1、3、6 和 12 个月的有效率分别为 68.6%、74.3%、77.1%和 62.8%，明显高于传统放化疗组（p＜0.05）。接受（125）I 种子植入的患者中位生存期为 29.0 个月，而接受传统放化疗的患者中位生存期为 19.0 个月。两组间差异有统计学意义。两种治疗方法均无严重并发症或死亡，除（125）I 种子植入组有 1 例肿瘤区域周围脑出血。
2002 年 11 月至 2010 年 5 月，73 例复发性神经胶质瘤患者接受 CT 引导下（125）I 种子植入（35 例）或传统放化疗（38 例）治疗。治疗后随访，比较两组的疗效和生存率。特别监测（125）I 种子植入患者的不良反应。
CT 引导下（125）I 种子植入安全耐受，且与传统放化疗相比，疗效更优。这表明 CT 引导下（125）I 种子植入可能是治疗复发性神经胶质瘤的一种替代方法。
